After Hours
$
51.40
Change
+2.44 +4.98%
Volume
Volume 19,914
Aug 9, 2022, 7:25 p.m.
Quotes are delayed by 20 min
Today's close
$ 54.50
$ 48.96
Change
-5.54 -10.17%
Day low
Day high
$48.56
$53.77

52 week low
52 week high
$27.65
$133.82

Market cap
$5.55B
Average volume
1.14M
P/E ratio
N/A
Rev. per Employee
$297,254
EPS
-5.41
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on GH
-
Illumina Will Be Fine Despite Recent Concerns, Says CEO
- Barron's Online
-
Illumina Stock Plunges Despite Strong Results, Gene-Sequencing Sales
- Barron's Online
-
How Exact Sciences Aims to Keep Its Lead in Cancer Tests
- Barron's Online
-
I Tried a New Test That Screens for 50 Kinds of Cancer. What I Learned.
- Barron's Online
-
Cancer-Test Maker Exact Sciences Saw Strong Revenue Growth
- Barron's Online
-
Illumina Stock Is Slipping. Biotech Investors Are Hard to Impress.
- Barron's Online
-
This investor crushes his fund’s benchmark with these 10 stocks
- Michael Brush
-
Will Illumina’s Purchase of Grail Kill Cancer-Test Competition?
- Barron's Online
-
How a 53-Year-Old Growth Fund Takes the Long View
- Barron's Online
-
How Natera Is Defending Its Lead in a $15B Cancer-Testing Market
- Barron's Online
-
Guardant Health initiated at market perform at Raymond James
- Tonya Garcia
-
Grail Will Begin Selling Its Multi-Cancer Blood Test
- Barron's Online
-
How a Simple Blood Test Could Reduce Cancer Deaths
- Barron's Online
-
FTC's Challenge of Illumina Is a Boost for Rivals in Cancer Test Race
- Barron's Online
- Loading more headlines...
Other News on GH
-
Warning: GH is at high risk of performing badly
- Seeking Alpha
-
Why Guardant Health Stock Was So Healthy Today
- Motley Fool
-
- Edgar Online - (EDG = 10Q, 10K)
-
Guardant Health Q2 2022 Earnings Preview
- Seeking Alpha
-
Guardant Health: Recent Developments Signal More Upsides
- Seeking Alpha
-
Warning: GH is at high risk of performing badly
- Seeking Alpha
-
Guardant Health: Pending Recession, May Hurt Cancer Care Demand
- Seeking Alpha
-
Warning: GH is at high risk of performing badly
- Seeking Alpha
-
Lantheus Holdings Rules The Medical Diagnostics Business World
- Seeking Alpha
-
Warning: GH is at high risk of performing badly
- Seeking Alpha
-
Warning: GH is at high risk of performing badly
- Seeking Alpha
-
Why Shares of Guardant Health Dropped 33.6% in May
- Motley Fool
- Loading more headlines...
Earnings Announcement
Press Releases on GH
-
Guardant Health Reports Second Quarter 2022 Financial Results
- BusinessWire - BZX
-
Liquid Biopsy Market Share to Witness Steady Rise by 2029
- AmericaNewsHour
-
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
- BusinessWire - BZX
-
Gamehost Announces Regular Monthly Dividend For July
- ACCESSWIRE
-
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
- BusinessWire - BZX
-
Steve E. Krognes Joins Guardant Health Board of Directors
- BusinessWire - BZX
-
Gamehost Announces AGM Voting Results
- ACCESSWIRE
-
Gamehost Announces Regular Monthly Dividend for June
- ACCESSWIRE
-
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
- BusinessWire - BZX
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com